Compare FCPT & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCPT | IMNM |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | N/A | N/A |
| Metric | FCPT | IMNM |
|---|---|---|
| Price | $24.96 | $22.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $27.80 | ★ $32.10 |
| AVG Volume (30 Days) | 854.3K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.26 | N/A |
| Revenue Next Year | $4.60 | $11.53 |
| P/E Ratio | $22.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.78 | $5.15 |
| 52 Week High | $29.81 | $27.65 |
| Indicator | FCPT | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 55.91 | 46.00 |
| Support Level | $23.97 | $24.03 |
| Resistance Level | $25.44 | $25.21 |
| Average True Range (ATR) | 0.55 | 1.54 |
| MACD | -0.05 | -0.52 |
| Stochastic Oscillator | 59.24 | 13.96 |
Four Corners Property Trust Inc is a real estate investment trust predominantly engaged in the ownership, acquisition and leasing of restaurant and retail properties. The company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries. The firm operates through two segments namely, real estate operations and restaurant operations. The real estate operations segment consists of rental revenues generated by leasing restaurant and retail properties to tenants. The restaurant operations segment is conducted through a taxable REIT subsidiary (TRS) and consists of Kerrow Restaurant Operating Business. The firm generates majority of the revenue from the real estate operations segment.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.